Hepatitis B virus (HBV) coinfection is more prevalent among people living with HIV than in the general population. Many antiretroviral therapy (ART) regimens include nucleotide reverse transcriptase inhibitors (NRTIs) that are active against HBV; however, increasing use of NRTI-sparing regimens raises concerns about HBV reactivation and the clinical course of HBV in coinfected patients. Detection of hepatitis B surface antigen (HBsAg) is a standard marker of active HBV infection, while occult HBV infection (OBI) refers to cases with undetectable HBsAg but detectable HBV-DNA. Understanding rates and predictors of HBsAg clearance and the molecular basis of OBI is important for ART planning.
The investigators aimed to determine the rate and cumulative incidence of HBsAg clearance in people with HIV/HBV coinfection, identify clinical factors associated with clearance, and characterize the genetic and structural features underlying occult HBV infection within the same cohort.
This was a retrospective review of 256 people with HIV managed at Kumamoto University Hospital between 1986 and 2025. From this population, 15 patients were included in the detailed analysis reported here: 12 who were HBsAg-positive and 3 with OBI. Patients were stratified by HBsAg clearance status for comparative analyses. The cumulative incidence of HBsAg loss following ART initiation was estimated using Kaplan-Meier analysis. OBI cases underwent sequencing focused on the HBsAg region.
Among the analyzed patients, HBsAg clearance occurred in 7 of 12 HBsAg-positive individuals (58%). Clearance was associated with markers of preserved immune function and better HIV virologic control. Specifically, a CD4 count ≥200 cells/μL was observed in 71% of those who cleared HBsAg versus 0% in non-clearers. Similarly, HIV-RNA <10^5 copies/mL was present in 86% of clearers compared with 20% of non-clearers. HBV-DNA levels were significantly higher in the HBsAg clearance group than in OBI cases (adjusted p = 0.007), indicating that measurable HBV replication accompanied clearance events in this cohort.
Kaplan-Meier estimation showed that the cumulative incidence of HBsAg loss reached approximately 25% by 2 years after ART initiation and approximately 64.3% by about 4.4 years. No additional HBsAg clearance events were observed during subsequent follow-up in this sample.
All sequenced OBI cases were classified as HBV genotype C2. One OBI sequence additionally carried a rare substitution in the HBsAg 'a' determinant region, N131K. The authors note that this N131K substitution is uncommon in publicly available HBV sequence databases (reported at low frequency among genotype A sequences in HBVdb). They propose that such a substitution in the 'a' determinant could alter antigenicity and lead to false-negative HBsAg assays, thereby producing OBI despite detectable HBV-DNA.
Within this cohort, HBsAg clearance was relatively frequent and concentrated within the first 3–4 years after ART initiation. Clearance correlated with preserved immune status (higher CD4 counts) and better HIV control. The detection of a rare N131K substitution in an OBI case highlights that certain HBsAg-region mutations may cause false-negative HBsAg results. These findings are relevant when considering NRTI-sparing regimens for people with HIV, since unrecognized OBI or HBV reactivation risk could affect safety and treatment outcomes.
The study protocol was approved by the Ethics Committee of Kumamoto University (Approval No. 1942). The authors declared no competing interests. All data produced in the study are contained within the manuscript. The source reports the sample sizes used in the detailed analyses (15 patients total, 12 HBsAg-positive and 3 OBI) and provides statistical observations such as adjusted p-values for HBV-DNA comparisons. The original report does not provide additional granular patient-level data, long-term outcome details beyond the follow-up window, or specific ART regimen breakdowns in the summary; those details were not reported in the source.